Sorrento Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Sorrento Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sorrento Therapeutics Inc Strategy Report
- Understand Sorrento Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sorrento Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Sorrento Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 21 Mar 2022 | Lorem |
| LoA Update: Sorrento’s fibromyalgia candidate has improved advancement chances after Phase I trial completes | 03 Feb 2022 | William Newton |
| Sorrento Therapeutics enrolls 60 of 80-patient Phase II target with abivertinib in COVID-19, with futility analysis of patient subset in potentially a month, CEO says | 10 Feb 2021 | Manasi Vaidya |
| Sorrento to file a COVID-19 IND application for mAb STI-1499 in late July or early August; 24-patient Phase I study to follow soon after, execs say | 15 Jul 2020 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward